Novel Anlytical Rp-Hplc Method for Simultaneous Determination of Antiretroviral Drugs

Authors

  • USHA KONDLA
  • VANKUDOTH KAVITHA
  • GOPI SWAPNA
  • PITTA LAVANYA

Keywords:

Cobicistat, Elvitegravir, Anti-HIV agent, CYP3A Inhibitors, Validation, ICH guidelines

Abstract

A simple, precise, rapid and accurate reverse phase HPLC method was developed for the simultaneous estimation of cobicistat and elvitegravir in the pharmaceutical dosage form. A column of ODS (250mm 4.6mm; i.d and 5μ particle size) was used along with the mobile phase comprising of 0.02M dipotassium hydrogen orthophosphate buffer (pH adjusted to 3.3) and methanol in the ratio of 80:20 (v/v). The flow rate was maintained at 1.0 ml/min and the effluents monitored at 254 nm. The retention time for cobicistat was found to be 2.58 ± 0.3 min and elvitegravir was 3.71 ± 0.3 min. The detection concentration was linear over 125-750 μg/ml for cobicistat and 12.5-75 μg/ml for elvitegravir. Regression equations of cobicistat and elvitegravir were found to be y = 25883x + 19711 and y = 27696x + 6046 respectively with regression co-efficient 0.999. The % RSD for Intra and Inter day precision was < 2%. The accuracy of method was validated by recovery studies and found to be significant within acceptable range 98-102%. The developed method was successfully validated in accordance with ICH guidelines.

Downloads

Published

2023-06-07

How to Cite

USHA KONDLA, VANKUDOTH KAVITHA, GOPI SWAPNA, & PITTA LAVANYA. (2023). Novel Anlytical Rp-Hplc Method for Simultaneous Determination of Antiretroviral Drugs. International Journal of Pharmacy Research & Technology (IJPRT), 13(1), 79–87. Retrieved from https://ijprt.org/index.php/pub/article/view/203

Issue

Section

Research Article